Eris Lifesciences Ltd

Eris Lifesciences Limited's investor presentation for Q2 and H1 FY27 highlights revenue growth of 14.1% YoY in Domestic Branded Formulations (DBF) with EBITDA margin at 35.7%, down 191 bps YoY. The DBF segment reported a 14.2% YoY revenue increase in H1 FY27, with EBITDA margin at 35.2%. The company noted a sequential improvement in gross margin, rising 100 bps from Q1 to Q2 FY27, attributed to the commercialization of the Bhopal facility and out-licensing to Zorvia Healthcare. Excluding Zorvia, DBF growth reached 16.5% in Q2. In the International Business, the EU CAPA shutdown is planned for Q3, with no cancellations in the CDMO pipeline. The Swiss Parenterals unit's construction is on track, with production expected by April 2027. Consolidated revenue grew 12.6% YoY in Q2, with PAT up 39.2% YoY. The company reported a 10-day reduction in consolidated debtor days and a net debt reduction of ₹111 cr in H1. The presentation includes forward-looking statements about future performance, subject to risks and uncertainties.

The summary presents factual financial results, operational updates, and forward-looking statements without overtly positive or negative language.